Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

UMOX™: A New Device for Preoxygenation

25. April 2013 aktualisiert von: Louis-Philippe Fortier, Maisonneuve-Rosemont Hospital

Background - Preoxygenation is performed before general anesthesia to increase the oxygen reserves of the body and prolong the safe period of apnea without hypoxia. However, it is often impossible to obtain a perfect face mask fit, and optimal end-tidal fractional oxygen concentration (EtO2) are not attained. The investigators designed a new oropharyngeal preoxygenation device, UMOX™, to avoid leaks during preoxygenation. In this study, the investigators compared the efficacy of UMOX™ with that of a conventional face mask.

Methods - In 50 healthy volunteers breathing 100% oxygen from a circle absorber system for a 5 minute-period, the investigators compared preoxygenation using the 1) a conventional mask; 2) UMOX™ without any instruction; 3) UMOX™ with instruction on mouth breathing; and 4) UMOX™ with a nose clip, in random order. Each subject underwent all steps with a 10-minute rest period of room air breathing between each step. Inspired and end-tidal respiratory gases were measured every 10 seconds. EtO2 variation was analyzed using Anova.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Detaillierte Beschreibung

This study was as a single center, crossover, randomized trial. Following approval from research and ethics committee from our hospital and written consent from healthy subjects recruited, 50 consenting volunteers were enrolled over a three-month period, from: September 29, 2008 to November 5, 2008.

Subjects enrolled were of both genders, smokers and non-smokers, American Society of Anesthesiologists (ASA) physical status I or II, 18 to 65 years old. Nonrecruitment depended on the presence of any craniofacial abnormality, facial hair (beard or moustache) or absence of teeth. Well-controlled non-severe asthma was not a criterion for exclusion.

The trial was conducted in an operating room, using the Dräger Fabius GS (Dräger, Canada), anesthesia machine in a usual set up with the operating table. The investigators used a, patient circuit system consists of 1.5-L lime soda absorber connected to disposable corrugated tubing and a 2-L breathing bag. Gases were analyzed through a Marquette Medical Systems™ SAM module (GE Healthcare), volumes monitored with a GE Respirator Mechanics-M (GE Healthcare) and SpO2 measured with a Nellcor™ (Covidien) pulse oximetry positioned on a finger. Preoxygenation procedures were explained to the subjects and ample time was allowed so they could become familiar with the mask and mouth piece. Set up for the measure was conducted by the same experimenter. Subjects laid supine and preoxygenation was performed with fresh gas flow: 100% oxygen (O2) 10L/minute, administered trough facemask or mouth piece sequentially in a random order. Randomization was established with a random assignment table (ww.randomization.com). The envelope was open as the subject entered the operating room (OR). At the beginning and between each step, the anesthesia circuit was flushed with 100% (O2). Each subject went through all steps in random order, each requiring a 5-min period of: 1) tidal breathing using the facemask (TVFM); 2) tidal volume breathing with the UMOXTM mouthpiece (TVMP); 3) tidal volume breathing with the UMOXTM mouthpiece and verbal instructions to favor mouth breathing (TVMPMB); (4) tidal volume breathing with the UMOXTM mouthpiece and a nose clip (TVMPNC). The experimenter conducting the steps instructed participants to create a seal with their lips around the mouthpiece and readjusted the facemask when the subject signalled a discernable leak. Each step was interrupted by 10 minutes of breathing normal room air to allow for return to original respiratory status. Continuous recording of experimental measures, displayed on the anesthesia monitoring system, was done on digital films (Canon PowershotS5 IS™). For the purpose of our trial, 10 seconds intervals were considered adequate for following preoxygenation trends. End-tidal O2 was measured continuously for 5 min. We have also evaluated the level of satisfaction of the subject with each technique using a 1-4 scale.Participants were asked to asses their comfort by showing the associated number with their fingers. Finally we described the performance of the facemask ventilation technique as reported by the experimenter on a scale of 1 to 4.Primary outcome was the end-tidal O2 at the end of the 5-minutes preoxygenation period. Secondary outcomes included endtidal O2 as a function of time, the number of subjects reaching at least 87% EtO2, subject satisfaction and ease of ventilation.

Based on the few studies available on different preoxygenation technques, the end-tidal oxygen fraction standard deviation can range from 5% to about 20% depending on the device used for preoxygenation3,4,14,15. Assuming a 12% value for standard deviation, sample size calculations were made for Type I and Type II errors of 5% and 20%, respectively (power of 80%). From these numbers and taking account that we would rely on multiple comparisons, the power analysis suggested that 50 subjects would allow us to find a difference between groups around 9%. The 9nvestigators analyzed the EtO2 final value with one-way ANOVA followed by the Tukey's Multiple Comparisons test. Percentage of participants reaching at least 87% EtO2 are described with survival curves compared with Kaplan-Meier log rank test. Tolerance is presented using Kruskal-Wallis with Dunn's Multiple Comparisons test.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

49

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Quebec
      • Montréal, Quebec, Kanada, H1T 2M4
        • Maisonneuve-Rosemont Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Both genders
  • smokers and non-smokers
  • American Society of Anesthesiologists (ASA) physical status I or II
  • 18 to 65 years old.

Exclusion Criteria:

  • Presence of any craniofacial abnormality
  • facial hair (beard or moustache) or absence of teeth.
  • Well-controlled non-severe asthma was not a criterion for exclusion.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Crossover-Aufgabe
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Schein-Komparator: Tidal breathing using the facemask
Control
Experimental: Tidal volume breathing with the UMOXTM, device, no instruction
First experimental measure
Device used to perform preoxygenation in the operating room context
Andere Namen:
  • Umox
Experimental: Tidal volume breathing with the UMOXTM device, instructions
Second experimental measure
Device used to perform preoxygenation in the operating room context
Andere Namen:
  • Umox
Experimental: Tidal volume breathing with the UMOXTM, device, nose clip
Third experimental measure
Device used to perform preoxygenation in the operating room context
Andere Namen:
  • Umox

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
The primary outcome measurement was the evolution of endtidal oxygen fraction during a 5 minute preoxygenation procedure, measurements were done continuously, maximum values were recorded
Zeitfenster: The four steps were done sequentially, each step consisted of a 5 minute recording period under specific conditions, followed by a 10 minute pause before the next step
The goal of this study is to compare the efficacy of preoxygenation using the conventional mask with the mouthpiece of the UMOX™ oropharyngeal device. The primary outcome measurement was endtidal oxygen fraction. The investigators also evaluated the respective tolerability of the two preoxygenation instruments in healthy volunteers. The measures were not part of a surgical procedure, participants were volunteers participating in this experimental design. No follow-up step was included in this protocol.
The four steps were done sequentially, each step consisted of a 5 minute recording period under specific conditions, followed by a 10 minute pause before the next step

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
The investigators also evaluated the respective tolerability of the two preoxygenation instruments in healthy volunteers with a short questionnaire
Zeitfenster: The four steps were done sequentially, each step consisted of a 5 minute recording period under specific conditions, followed by a 10 minute pause before the next step
The four steps were done sequentially, each step consisted of a 5 minute recording period under specific conditions, followed by a 10 minute pause before the next step

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Louis P Fortier, MD, MSc, Université de Montréal

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. September 2008

Primärer Abschluss (Tatsächlich)

1. November 2008

Studienabschluss (Tatsächlich)

1. November 2008

Studienanmeldedaten

Zuerst eingereicht

27. Februar 2013

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

25. April 2013

Zuerst gepostet (Schätzen)

26. April 2013

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

26. April 2013

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

25. April 2013

Zuletzt verifiziert

1. Januar 2013

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 06108

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur facemask

Abonnieren